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Summary
Perturbations in hepatic lipid homeostasis are linked to the development of obesity-related steatohepatitis. Mutations in the
gene encoding lipin 1 cause hepatic steatosis in fldmice, a genetic model of lipodystrophy. However, themolecular function
of lipin 1 is unclear. Herein, we demonstrate that the expression of lipin 1 is induced by peroxisome proliferator-activated
receptor g (PPARg) coactivator 1a (PGC-1a), a transcriptional coactivator controlling several key hepatic metabolic path-
ways. Gain-of-function and loss-of-function strategies demonstrated that lipin selectively activates a subset of PGC-1a
target pathways, including fatty acid oxidation andmitochondrial oxidative phosphorylation, while suppressing the lipogenic
program and lowering circulating lipid levels. Lipin activates mitochondrial fatty acid oxidative metabolism by inducing
expression of the nuclear receptor PPARa, a known PGC-1a target, and via direct physical interactions with PPARa and
PGC-1a. These results identify lipin 1 as a selective physiological amplifier of the PGC-1a/PPARa-mediated control of
hepatic lipid metabolism.Introduction
Overwhelming evidence links obesity-related perturbations in
hepatic lipid homeostasis to nonalcoholic fatty liver disease
(NAFLD). The incidence of NAFLD has risen dramatically, coin-
cident with the recent epidemic of obesity in the U.S., becoming
the most common cause of liver disease (Angulo, 2002; Clark
et al., 2002). It is now estimated that 25% or more of the general
population and up to 75% of clinically obese patients have de-
veloped NAFLD (Browning and Horton, 2004; Youssef and
McCullough, 2002; Zafrani, 2004). The pathogenic mechanisms
linking obesity to NAFLD are likely related to an oversupply of
fatty acid delivery that exceeds the capacity for hepatic fatty
acid oxidation, leading to triglyceride accumulation within hepa-
tocytes. Moreover, obesity-related hepatic insulin resistance
further exacerbates fatty acid oversupply by inappropriately
de-repressing hepatic lipogenesis (Shimomura et al., 2000).
The capacity for mitochondrial fatty acid b-oxidation is a criti-
cal determinant of hepatic lipid balance in the context of high
levels of circulating fatty acids and triglyceride-rich lipoproteins.
The expression of genes encoding enzymes involved in hepatic
b-oxidation is under dynamic transcriptional control by the
nuclear receptor peroxisome proliferator-activated receptor a
(PPARa) (Desvergne and Wahli, 1999). The activity of PPARa
is regulated atmultiple levels including fatty acid ligand availabil-
ity and interaction with the highly-inducible transcriptional coac-
tivator, PPARg coactivator-1a (PGC-1a) (Vega et al., 2000). In
addition to PPARa, PGC-1a coactivates a variety of transcrip-
tion factors controlling cellular energy metabolism through di-
rect protein-protein interactions (Lin et al., 2005a; SpiegelmanCELL METABOLISM 4, 199–210, SEPTEMBER 2006 ª2006 ELSEVIER INand Heinrich, 2004). Although PGC-1a is expressed at relatively
low levels in adult liver under normal conditions, its expression is
markedly activated during fasting and diabetes (Herzig et al.,
2001; Yoon et al., 2001) consistent with its role as an activator
of genes involved in gluconeogenesis and fatty acid oxidation.
Recent work has demonstrated that mice deficient for either
PPARa (Kersten et al., 1999; Leone et al., 1999) or PGC-1a
(Leone et al., 2005) exhibit fasting-induced hepatic steatosis.
Fasting-induced lipid accumulation in these models is likely
due to diminished capacity for fatty acid catabolism in the
face of increased hepatic delivery of free fatty acids, illustrating
the critical role of the hepatic PPARa/PGC-1a system in match-
ing fatty acid oxidative capacity to substrate availability.
The protein encoded by the Lpin1 gene (lipin 1) has been im-
plicated in the regulation of cellular lipid metabolism in a variety
of tissues, including liver. Lpin1 was discovered using a posi-
tional cloning approach to identify the genetic mutation respon-
sible for the fatty liver dystrophic (fld) mouse phenotype (Peterfy
et al., 2001). Fld mice exhibit life-long deficiency in adipocyte
differentiation (Reue and Peterfy, 2000; Reue et al., 2000),
peripheral neuropathy (Langner et al., 1991), circulating hyper-
lipidemia (Langner et al., 1989), and neonatal hepatic steatosis
associated with diminished rates of hepatic fatty acid oxidation
(Rehnmark et al., 1998). Conversely, transgenic lipin 1 overex-
pression in skeletal muscle or white adipose tissue exacerbates
high-fat diet-induced obesity (Phan and Reue, 2005). In higher
organisms, genes encoding three lipin family members (lipin 1,
lipin 2, and lipin 3) have been identified (Peterfy et al., 2001). In
addition, a splice variant lpin1 transcript encodes an alternative
form of this protein containing an insertion of 33 amino acidsC. DOI 10.1016/j.cmet.2006.08.005 199
A R T I C L E(lipin 1b) (Huffman et al., 2002; Peterfy et al., 2005) that may
influence its sub-cellular localization and function (Peterfy
et al., 2005).
Recently, the yeast homolog of lipin (SMP2 or Pah1) was re-
vealed to have enzymatic activity as a phosphatidic acid phos-
phohydrolase (PAP) (Han et al., 2006). PAP proteins catalyze the
formation of diacylglycerol from phosphatidic acid - the penulti-
mate step in triglyceride synthesis. Defects in other steps in the
triglyceride (TAG) synthesis pathway are known to result in lipo-
dystrophy or block adipocyte differentiation (Gale et al., 2006;
Vergnes et al., 2006) and this aspect of lipin biology could ex-
plain defects in adipose tissue development in the fld mouse.
However, the relevance of this activity in vivo is still unclear.
Several lines of evidence also suggest a nuclear function for
lipin 1. Lipin proteins contain a putative nuclear localization sig-
nal and lipin 1 is nuclear-localized in HEK293 and 3T3-L1 cells
(Peterfy et al., 2005, 2001). Chromatin immunoprecipitation
(ChIP) analyses have recently shown that a yeast homolog of
lipin (SMP2) is associated with the promoter regions of genes
involved in phospholipid biosynthesis (Santos-Rosa et al.,
2005), but lacks nucleic acid-interacting domains required for
direct DNA interactions. The specific nuclear functions of lipin
1, including potential mechanisms of transcriptional control,
also remain to be delineated.
Using an unbiased gene expression profiling approach, we
found that lipin 1 is a hepatic target of the transcriptional coac-
tivator, PGC-1a. Hepatic lipin 1 gene expression is induced by
fasting, glucocorticoids, and diabetes in a PGC-1a-dependent
manner. Lipin 1 is shown to activate expression of many genes
involved in mitochondrial fatty acid oxidative metabolism via
transcriptional activation of the gene encoding PPARa and
through direct cooperative interactions with PPARa and PGC-
1a. These studies place lipin 1 in a key position within the
PPARa/PGC-1a regulatory pathway and implicate this factor
in the physiologic control of hepatic fatty acid metabolism and
oxidative phosphorylation.
Results
Lipin 1 is a fasting-induced PGC-1a target gene in liver
Recently, we found that mice deficient for the transcriptional
coactivator PGC-1a (PGC-1a2/2mice) develop fasting-induced
hepatic steatosis related to diminished capacity for mitochon-
drial fatty acid b-oxidation (Leone et al., 2005). To identify
PGC-1a target genes relevant to this hepatic phenotype, gene
expression profiling (microarray) studies were performed using
RNA isolated from livers of fed and fasted wild-type (WT) and
PGC-1a2/2mice. These analyses revealed that the gene encod-
ing lipin 1 was robustly induced by fasting in WT mice, but only
minimally activated in PGC-1a2/2mice (data not shown). North-
ern andWestern blotting studies confirmed that PGC-1awas re-
quired for the full fasting-induced activation of lipin 1 expression
(Figure 1A). Lipin expression was also strongly induced in a
PGC-1a-dependent manner 5 hr after an acute intraperitoneal
injection of the synthetic glucocorticoid dexamethasone
(Figure 1B), which stimulates PGC-1a expression (Bernal-Mizra-
chi et al., 2003). Furthermore, hepatic lipin 1 expression was
increased in mouse models of type 1 and type 2 diabetes melli-
tus (Figure 1C), conditions in which hepatic PGC-1a expression
and activity is known to be elevated (Herzig et al., 2001; Rhee
et al., 2003; Yoon et al., 2001). Finally, adenoviral-mediated200overexpression of PGC-1a markedly induced lipin 1 protein
levels in primary mouse hepatocytes and C2C12 skeletal myo-
tubes (Figure 1D). Collectively, these results indicate that
PGC-1a is sufficient and required for the fasting-induced activa-
tion of lipin 1 gene expression.
Lipin 1 activates the PPARa gene regulatory
pathway in liver
To identify relevant pathways downstream of lipin 1, the long
form of lipin 1 protein (lipin 1b), which is the predominant lipin
1 isoform in liver (Huffman et al., 2002; Peterfy et al., 2005),
was overexpressed in liver of mice using an adenoviral vector
(Ad-lipin). Gene expression array studies revealed that lipin 1b
induced the expression of 1751 genes and repressed 2235
genes (data not shown). Amongst the genes activated by lipin
1 were the nuclear receptor PPARa (Ppara) and many of its tar-
get genes involved in fatty acid uptake and utilization (Table S1
in the Supplemental Data available with this article online). In
addition, lipin 1 activated the broad program of genes encoding
TCA cycle enzymes and proteins involved in mitochondrial
oxidative phosphorylation - known targets of PGC-1a (Koves
et al., 2005; Lin et al., 2005a). Forced expression of lipin 1 also
led to diminished expression of several genes involved in fatty
acid and TAG synthesis (Table S1).
Northern blotting and quantitative real-time RT-PCR analyses
were performed to validate the results of the microarray studies.
As predicted by the profiling results, infection with Ad-lipin 1
increased hepatic Ppara gene expression and the expression
of several PPARa target genes involved in fatty acid utilization
(Cpt1a, Acadvl, Acadm, Acox1, and Fabp1)(Figure 2A). Quanti-
tative RT-PCR studies confirmed that expression of genes en-
coding several TCA cycle enzymes (Sdha, Idh3a, and Mdh2)
and additional genes involved in the control of mitochondrial
metabolism, including mitochondrial transcription factor A
(Tfam), a nuclear-encoded transcription factor controlling mito-
chondrial gene transcription, and downstream genes involved in
oxidative phosphorylation (Cycs, Cox2, and Atp5b) were signif-
icantly induced by lipin activation (Figure S1). Conversely, lipin 1
activation markedly diminished expression of genes involved in
de novo lipogenesis (Srebf1 and Fasn), fatty acid desaturation
(Scd1), and, to a lesser extent, lipoprotein secretion (Apoa4 ;Fig-
ure 2A). Collectively, these results suggest that lipin activates
expression of PPARa/PGC-1a target genes involved in mito-
chondrial fatty acid catabolism and downstream mitochondrial
pathways involved in electron transport and ATP production
while suppressing the lipogenic and lipid secretion programs.
To investigate functional correlates of the gene expression
results, a series of metabolic studies were performed. As ex-
pected, palmitate oxidation rates were significantly increased
in hepatocytes isolated from Ad-lipin-infected mice (Figure 2B).
The lipin-mediated increase in b-oxidation was blocked by eto-
moxir, an inhibitor of mitochondrial fatty acid import. Also con-
sistent with an activation of hepatic fatty acid oxidation, levels
of plasma b-hydroxybutyrate, a product of ketogenesis, were
significantly elevated with lipin 1 overexpression (Figure 2C).
Conversely, rates of fatty acid synthesis, as quantified by 14C-
acetate incorporation, were diminished in hepatocytes overex-
pressing lipin 1 (Figure 2D). Moreover, lipin 1 activation led to
diminished rates of hepatic TAG secretion in vivo (Figure 2E)
and a significant reduction in circulating triglyceride (TAG) and
nonesterified fatty acid (NEFA) levels (Figure 2F). Interestingly,CELL METABOLISM : SEPTEMBER 2006
Lipin regulates hepatic lipid metabolismFigure 1. Lipin 1 is a fasting-induced PGC-1a target
gene in liver
A) Representative autoradiographs from Northern
(top) and Western (bottom) blotting analyses using
hepatic RNA or protein from WT and PGC-1a2/2
mice given ad libitum access to food or fasted 24 hr.
B) Graph depicts results of RT-PCR analyses to
quantify lipin 1 mRNA levels using liver RNA isolated
from WT and PGC-1a2/2 mice 5 hr after injection
with saline or dexamethasone. Values are normal-
ized (= 1.0) to control expression levels. *p < 0.05
versus vehicle-injected controls. yp < 0.05 versus
WT dexamethasone-treated mice.
C) Results of RT-PCR analyses using liver RNA iso-
lated from control and diabeticmice. Type 1 diabetes
was induced by streptozotocin injection and db/db
mice were used as a model of type 2 diabetes.
*p < 0.05 versus controls.
D)Results of Western blotting analyses using protein
isolated from primary mouse hepatocytes (top) or
C2C12 skeletal myotubes (bottom) infected with
Ad-GFP or Ad-PGC-1a (schematized at the top)
and uninfected controls as indicated. Blots were
sequentially probed with antibodies shown at left.steady-state TAG content of liver tissue was actually signifi-
cantly increased by lipin 1 (Figure 2F), which seems to contradict
the effects of lipin 1 on rates of fatty acid catabolism and syn-
thesis. This observation could be explained by hepatic TAG se-
questration secondary to diminished TAG secretion, increased
fatty acid uptake, or the PAP activity of lipin 1. Collectively, these
data indicate that activation of lipin 1 in liver stimulates mito-
chondrial fatty acid catabolism while suppressing de novo lipo-
genesis and TAG secretion.
Deactivation of lipin 1 blunts PPARa target gene
expression
The role of lipin in the transcriptional regulation of hepatic
metabolism was further assessed using loss-of-function ap-
proaches. The expression of PPARa/PGC-1a target genes
was examined in liver of 7-day-old fld mice, which lack lipin 1
and exhibit hepatic steatosis. The expression of Ppara and sev-
eral genes involved in mitochondrial fatty acid oxidation (Cpt1a,
Acadvl, Acadl, Acadm, and Fabp1) was diminished in liver of
fld mice (Figure 3A), while expression of Apoa4 was induced,
consistent with a previous report (Langner et al., 1989).
To further understand the role of lipin 1 in the control of he-
patic fatty acid metabolism, we designed two adenoviral shRNA
constructs (sh594 and sh896) to ‘‘knockdown’’ mouse lipin 1
mRNA. Although little effect on lipin 1 expression was observed
at baseline, both constructs abolished the induction of lipin 1
protein expression in fasted mice in vivo (Figure 3B). Acute he-
patic lipin 1 deficiency in fasted mice significantly diminished
the fasting-induced activation of Ppara and several PPARa/
PGC-1a target genes including Acadvl, Acadm, and Fabp1 but
only modestly impacted expression of another target, Cpt1a
(Figure 3B). The increase in plasma b-hydroxybutyrate levelsCELL METABOLISM : SEPTEMBER 2006observed with fasting was also significantly blunted by lipin
shRNA (Figure 3C). Lipin 1 shRNA administration resulted in
a significant increase in hepatic and circulating TAG levels fol-
lowing a 24 hr fast (Figure 3D). Taken together with the observed
robust increase in hepatic lipin 1 expression with fasting, these
data suggest that lipin 1 plays a critical role in the activation of
fatty acid oxidative pathways that occurs with acute fasting.
Lipin 1 activates transcription of the PPARa gene in
cooperation with PGC-1a
To determine whether activation of PPARa gene expression by
lipin was due to direct transcriptional activating effects, a human
PPARa promoter-luciferase reporter was cotransfected into
HepG2 hepatocytes with a lipin 1 expression vector in the pres-
ence or absence of PGC-1a. We have shown previously that
PGC-1a coactivates the PPARa promoter (Huss et al., 2004).
Lipin 1 activated the PPARa promoter by approximately 2-
fold, an effect that was additive with PGC-1a-mediated coacti-
vation (Figure 4A). The best-characterized regulatory element
controlling PPARa gene expression is a nuclear receptor re-
sponse element originally named the hepatocyte nuclear factor
4 response element (HNF4-RE) that binds and responds to
HNF4a, PPARa, and estrogen-related receptor a (ERRa) (Huss
et al., 2004; Pineda Torra et al., 2002). Mutation of the PPARa
gene promoter HNF4-RE abolished activation by lipin (Fig-
ure 4A). Cotransfection studies revealed that lipin 1 also coacti-
vates HNF4a or PPARa, but failed to enhance ERRa-mediated
activation of the PPARa promoter (Figure 4B).
Given that a homolog of lipin (SMP2) associates with yeast
gene promoters (Santos-Rosa et al., 2005), we next sought to
determine whether mammalian lipin could function in an analo-
gous manner on the PPARa gene promoter using chromatin201
A R T I C L EFigure 2. Lipin 1 activates the hepatic PPARa gene
regulatory pathway
A) Representative autoradiographs from Northern
blotting studies using liver RNA from mice injected
intravenously with adenovirus driving expression of
lipin 1 (LPN) or green fluorescent protein (GFP). Blots
were sequentially hybridized with the cDNA probes
listed at left. At right, values represent mean mRNA
levels determined by phosphorimaging analyses.
The Ad-lipin fold-change value is relative to the
normalized (= 1.0) value of GFP signal.
B) The graph depicts mean (6SEM) rates of palmi-
tate oxidation in isolated hepatocytes from mice
infected with either Ad-GFP or Ad-lipin under basal
conditions and following exposure to the mitochon-
drial fatty acid import inhibitor, etomoxir. *p < 0.05
versus GFP control.
C) Graph depicts plasma b-hydroxybutyrate (HB)
levels in mice infected with GFP or lipin 1 adenovirus.
D) Mean rates of de novo fatty acid synthesis from
14C-acetate in isolated hepatocytes infected with
lipin and/or GFP are displayed in the graph.
E) The graph depicts plasma triacylglyceride levels in
mice infected with Ad-GFP or Ad-lipin and treated
with Triton WR-1339 (at time 0) to inhibit lipoprotein
lipolysis. *p < 0.05 versus GFP control at the same
time.
F) Graphs depict mean levels of plasma triacylgly-
cerides (TAG) and Nonesterified fatty acids (NEFA)
or liver TAG (right) in mice following infection with
Ad-GFP or Ad-lipin after a 4 hr fast.immunoprecipitation (ChIP) studies. We probed for this interac-
tion using chromatin from hepatocytes isolated from fed or
fasted mice and PCR primers flanking the nuclear receptor
response element of the Ppara gene promoter (Huss et al.,
2004). ChIP studies demonstrated that lipin 1 was associated
with the Ppara promoter and was further enriched when chro-
matin from fasted mice was employed (Figure 4C). The specific-
ity of this assay was confirmed using chromatin from fasted lipin
1 shRNA-treated mice and mice infected with adenovirus over-
expressing lipin 1b. These data indicate that lipin 1 interacts
with the Ppara promoter in a region known to be transcription-
ally-activated by PGC-1a and nuclear receptors (Huss et al.,
2004; Pineda Torra et al., 2002). Given that lipin lacks DNA
binding domains, we suggest that this interaction is indirect
through transcription factor partners such as PPARa as
described below.
Lipin enhances PGC-1a-mediated coactivation of PPARa
We sought to determine whether lipin 1 also activated PPARa
via posttranslational mechanisms. To this end, a PPAR-respon-202sive reporter (ACO.3X.TKLuc) was transfected into HepG2 cells
in the presence or absence of lipin 1, PPARa, and/or PGC-1a
expression vectors. Lipin enhanced activation of the reporter
in the presence of PPARa, and to a greater extent when both
PPARa and PGC-1a were present (Figure 4D). Furthermore,
whereas lipin alone had no effect on the activity of a Gal4-
PPARa fusion protein, PGC-1a-mediated coactivation of the
Gal4-PPARa chimera was significantly enhanced by lipin 1
overexpression; indicating cooperativity among these factors
(Figure 4E). In sum, these studies suggest that lipin activates
PPARa via transcriptional and posttranslational mechanisms in
cooperation with PGC-1a.
Lipin physically interacts with PPARa
Co-immunoprecipitation (Co-IP) studies were performed with
adenoviral-driven, epitope-tagged proteins to determine
whether lipin 1 interacts directly with PPARa. Immunoprecipita-
tion of lipin co-precipitated PPARa, and to a lesser extent,
PPARg (Figure 5A). Similarly, PPARa or g co-precipitated lipin
1 (Figure 5A), indicating that lipin 1 interacts with multipleCELL METABOLISM : SEPTEMBER 2006
Lipin regulates hepatic lipid metabolismFigure 3. Deactivation of lipin 1 leads to diminished
expression of PPARa target genes in liver
A) Representative autoradiographs from Northern
blotting analyses using hepatic RNA from fed 7-
day-old fld/fld or age-matched littermate heterozy-
gote (fld/+) control mice. Blots were sequentially
hybridized with cDNA probes indicated at left.
B) Results of Western blotting analyses using protein
isolated from liver of mice infected with adenoviral
vectors driving expression of shRNA designed to
‘‘knock-down’’ LacZ (control) or lipin 1 (sh594 and
sh896) and given ad libitum access to food or fasted
for 24 hr. Blots were probedwith antibodies shown at
left. (below) Representative autoradiographs from
Northern blotting analyses using hepatic RNA from
mice injected intravenously with adenovirus driving
expression shRNA to ‘‘knock-down’’ LacZ or lipin 1.
Blots were sequentially hybridizedwith cDNA probes
indicated at left.
C and D) Graphs depict mean (6 SEM) levels of (C)
plasma b-HB, (D) plasma TAG (left), or liver TAG
(right) in mice infected with adenoviral shRNA vec-
tors given ad libitum access to food or fasted for 24
hr. *p < 0.05 versus LacZ shRNA mice with the
same dietary status.PPAR family members. GST pulldown assays further confirmed
these findings and demonstrated that the degree of the interac-
tion was not altered by the presence of exogenous ligand (data
not shown). The ligand-independent nature of the interaction is
consistent with transfection studies showing minimal ligand in-
fluence on lipin-mediated coactivation of PPARa (data not
shown).
To map the lipin domains mediating the interaction between
lipin and PPARa, GST pull-down studies were performed utiliz-
ing truncated forms of lipin protein. GST-lipin fusion constructs
containing either amino acids 1-641 (DC) or 640-924 (DN) of lipin
1 protein were employed. Whereas GST-lipinDN interacted
strongly with PPARa (Figure 5B), GST-lipinDC interacted only
weakly, suggesting that, although multiple interacting domains
exist, the primary lipin-PPARa interaction occurs between
amino acids 640–924 of the lipin protein. The intensity of the in-
teraction between GST-lipinDN and PPARa was roughly equiv-
alent to the previously-characterized (Vega et al., 2000) interac-
tion between GST-PGC-1a and PPARa (Figure 5B).
The region of lipin 1 mediating the interaction between lipin 1
and PPARa (residues 640-924) contains the previously de-
scribed C-terminal lipin domain (CLIP) that is homologous
across the lipin family (Figure 5C). We found that lipin 1a and
b as well as lipin 3 interacted with GST-PPARa in GST pull-
down assays (Figure 5D), suggesting that this is a general func-
tion of lipin proteins. In addition, both lipin 1a and b coactivated
PPARa in transfection studies (Figure 5E). Inspection of the
amino acid sequence of lipin 1 between residues 640 and 924
failed to reveal a signature a-helical leucine-rich (LXXLL) motif,CELL METABOLISM : SEPTEMBER 2006through which numerous nuclear receptor coregulators interact
with nuclear receptors (Savkur and Burris, 2004). However, two
conserved hydrophobic domains, an inverted IXXII (IISDI; resi-
dues 709–713) and an LXXIL (LGHIL; residues 722–726), were
identified within this region. Interestingly, the IIXXI domain over-
laps with the DXDXT consensus sequence of the PAP domain
(Figure 5C). When lipin 1 proteins containing site-directed
mutations of the LXXIL or IIXXI motifs were employed in pull-
down assays, we found that mutation of the IIXXI motif (I mut)
did not affect the ability of lipin 1 to interact with or coacti-
vate PPARa, whereas conversion of the LXXIL motif to LXXFF
(L mut) significantly diminished the interaction and coactivation
(Figures 5D and 5E). Site-directed mutation of the key aspartate
within the PAP catalytic domain of lipin 1 (D712E), did not impact
the interaction with, or coactivation of, PPARa (Figures 5D and
5E). The D712E, LXXFF, and FFXXI lipin 1 mutants all lack PAP
activity (Figure 5E). The observation that the FFXXI and D712E
mutants retain the ability to interact with and coactivate PPARa
indicate that the PAP activity of lipin 1 is distinct from its coac-
tivator function.
Hydrophobic residue-rich a-helical domains are known to
mediate interactions with the with the coregulator recruitment
domain (AF2) of nuclear receptors. GST pull-down assays utiliz-
ing a mutated PPARa protein in which the AF2 domain was de-
leted (PPARa 450) demonstrated a diminution in the intensity of
the interaction with GST-lipinDN (Figure 5F). However, a signifi-
cant interaction was still detected. The lipin-PPARa interaction
was nearly abolished when an additional 162 amino acids
(PPARa 288) comprising most of the ligand binding domain of203
A R T I C L EFigure 4. Lipin activates transcription of the PPARa
gene
Bars in all graphs represent mean (6 SEM) luciferase
activity in relative luciferase units (RLU) corrected for
renilla luciferase activity and normalized (= 1.0) to the
value of empty expression vector-transfected cells.
A) A schematic representation of the PPARa pro-
moter construct (Pa(H-H)-pGL3) is shown at top.
Pa(H-H)-pGL3 or a PPARa promoter-reporter har-
boring mutations in the HNF4-RE (Pa(HNF4mut)-
pGL3) was cotransfected into HepG2 cells in the
presence or absence of lipin 1 and/or PGC-1a
expression vectors. *p < 0.05 versus the value of
pcDNA control (vector). yp < 0.05 versus lipin 1 alone
or PGC-1a overexpression alone.
B) Results of studies in which Pa(H-H)-pGL3 was co-
transfected intoHepG2cellswith lipin1 and/orPPARa,
HNF4a, or ERRa expression vectors. *p < 0.05 versus
pcDNA controls (vector). yp < 0.05 versus corre-
sponding transcription factor overexpression alone.
C) The image depicts the results of ChIP assays us-
ing chromatin from hepatocytes of fed or fastedmice
infected with adenovirus driving expression LacZ
shRNA (Lac), lipin 1 shRNA (594), or lipin 1 overex-
pression (LPN). Chromatin bound proteins were im-
munoprecipitated using antibody directed against
lipin 1 or IgG control. ‘‘Input’’ represents 0.2% of
the total chromatin used in the IP reactions. For
PCR reactions for samples wherein lipin was overex-
pressed, the DNA input was reduced by 75%. PCR
primers were designed to amplify a region of the
Ppara gene promoter or exon 7 (negative control).
D) Schematic of the heterologous ACO.3X.TKLuc re-
porter, which contains a multimerized (33) PPARa-
responsive element derived from the promoter of
the mouse acyl-CoA oxidase gene linked to a viral
thymidine kinase (TK)minimal promoterwith a lucifer-
ase reporter is shown at top. HepG2 cells were co-
transfected with ACO.3X.TKLuc and lipin 1, PPARa,
and/or PGC-1a expression vectors. *p < 0.05 versus
pcDNA vector control.
E) A schematic depicting the heterologous UAS.
TKLuc reporter, which contains a multimerized (53)
yeast-derived Gal4-responsive element upstream
of TKLuc. UAS.TKLuc was cotransfected into CV1
cells with expression vector driving expression of
a Gal4-PPARa fusion protein (or Gal4 DNA binding
domain (DBD) control) in the presence or absence
of lipin 1 and/or PGC-1a expression vectors. *p <
0.05 versus pCDNA vector control. yp < 0.05 versus
PGC-1a overexpression alone.PPARa were deleted (Figure 5F). Collectively, these data sug-
gest that lipin physically interacts with PPARa via residues span-
ning the AF2 and ligand binding domains.
To determine whether lipin might also interact with other
PGC-1a partner proteins known to control expression of genes
involved in fatty acid oxidation and mitochondrial metabolism,
we examined the interaction of lipin 1 with PPARb, HNF4a,
ERRa and the glucocorticoid receptor (GR). GST-lipinDN inter-
acted strongly with PPARb, HNF4a, and GR, but only weakly
with ERRa (Figure 5F), a finding that coincides with the observa-
tion that lipin coactivates PPARa and HNF4a, but not ERRa, on
the PPARa promoter (Figure 4B). Thus, lipin 1 interacts selec-
tively with several PGC-1a partner proteins involved in the con-
trol of fatty acid oxidation.
Lipin interacts with PGC-1a
Co-IP studies were performed to determine whether lipin 1 inter-
acts directly with PGC-1a. An interaction between endogenous204lipin 1 and PGC-1a proteins was demonstrated in Co-IP studies
using liver protein isolated from fed and fasted mice (Figure 6A).
The quantity of PGC-1a and lipin 1 protein that immunoprecipi-
tated with a lipin 1 antibody was significantly increased under
fasting conditions, but only in WT mice as neither protein was
immunoprecipitated in PGC-1a-deficient mice (Figure 6A).
GST-lipinDN, but not the GST-lipinDC, protein interacted
strongly with full-length PGC-1a protein in pull-down assays
(Figure 6A). GST-lipinDN also interacted with a truncated
PGC-1a protein containing only the first 338 amino acids
(Figure 6B). However, the lipin/PGC-1a interaction diminished
in a stepwise manner when PGC-1a protein was further trun-
cated by deletions from amino acids 338 to 120, a region that
contains 3 LXXLL motifs (L1, L2, and L3) known to be required
for interactions with many PGC-1a partner proteins, including
nuclear receptors (Figure 6B). Combined site-directed muta-
tions in L1, 2, and 3 (mL1/2/3) markedly diminished the lipin-
PGC-1a interaction (Figure 6B).CELL METABOLISM : SEPTEMBER 2006
Lipin regulates hepatic lipid metabolismFigure 5. An LXXILmotif in lipin 1mediates the inter-
action between lipin 1 and the C terminus of PPARa
A) Results of Western blotting analyses using protein
isolated from HepG2 hepatocytes infected with Ad-
GFP, Ad-lipin 1, Ad-PPARa, or Ad-PPARg as indi-
cated at top. Proteins were immunoprecipitated us-
ing antibodies directed against fusion tags (HA-lipin
1, Flag-PPARa, or Flag-PPARg), followed by West-
ern blotting with antibodies raised against lipin 1 or
Flag proteins. Irrelevant IgG control IP is shown at
far right.
B) At top, schematics depicting GST-lipin fusion pro-
teins lacking the C terminus (lipinDC) or the N termi-
nus (lipinDN) are shown. The shaded areas denote
previously described conserved regions (NLIP and
CLIP). The upper autoradiograph depicts representa-
tive results of GST pull-down assays performed with
GST control or GST-lipin proteins and 35S-labeled
PPARa. The lower autoradiograph displays results
of GST pull-down assays comparing the interaction
between 35S-labeled PPARa and GST-lipinDN or
GST-PGC-1a(1-338). 10% of the input radiolabeled
protein was run in parallel lanes for comparison.
C) Amino acid sequence alignments of a portion of
the CLIP domain of lipin family proteins with IIXXI
and LXXIL motifs outlined by boxes. The consensus
(DXDXT) sequence for the PAP domain is under-
scored.
D) The autoradiograph depicts representative results
of GST pull-down assays performed with GST con-
trol or GST-PPARa fusion protein and recombinant
lipin proteins (wild-type and site-directed mutations).
E) (left) The graph depicts results of transfection
studies using HepG2 cells cotransfected with ACO,
33.TKLuc and expression vectors driving expres-
sion of various lipin 1 proteins (wild-type and site-
directed mutations). (right) The graph depicts mean
PAP activity in lysates of 293 transfected with vector
control (pCDNA-GFP) and various lipin 1 proteins
(wild-type and site-directed mutations). *p < 0.05
versus pcDNA vector control.
F) A representative autoradiograph from GST pull-
down assays performed with C-terminal fragment
of lipin fused to GST (GST-lipinDN) with 35S-labeled
PPARa containing 468 (full-length), 450, or 288
amino acids (see schematic at top) is shown. All trun-
cation mutants begin with aa 1 and mutant designa-
tions indicate C-terminal ends.
G) The autoradiograph depicts representative results
of GST pull-down assays performed with PPARa,
PPARb, ERRa, GR, and GST-lipin 1DN protein. The
quantity of input protein pulled down by lipin 1 cor-
rected to corresponding input lanes and normalized
(= 100%) to PPARa values, is shown at right.Lipin 1 augments the transcriptional activity of PGC-1a
As an initial step to investigate the mechanism whereby lipin 1
enhances the activity of PGC-1a, its effect on a Gal4-PGC-1a
chimeric protein was assessed. We found that lipin 1 coacti-
vated full-length Gal4-PGC-1a, as well as a Gal4-PGC-1a fusion
protein containing the first 120 amino acids of PGC-1a, in CV1
cells (Figure 6C). These results suggested that the direct interac-
tion of lipin 1with PGC-1a increases its transcriptional activating
function. Like PGC-1a, lipin 1 does not possess histone acety-
lase (HAT) activity. We therefore examined whether lipin 1
served to ‘‘dock’’ other coactivators possessing HAT activity.
We found that overexpressed lipin 1 co-immunoprecipitated
with endogenous p300 protein in IP using mouse liver extracts
(Figure 6D).CELL METABOLISM : SEPTEMBER 2006To determine whether the observed PGC-1a/lipin 1/p300 inter-
action increased HAT activity on a PPARa target promoter, ChIP
studies were performed on the Acadm gene promoter using anti-
bodies against lipin, PGC-1a, or acetylated histones and chroma-
tin isolated from fastedmouse liver. HepaticAcadm expression is
markedly induced by fasting (Leone et al., 1999) and as expected,
the association of lipin 1 and PGC-1a with the Acadm promoter
was increased in fasted mouse liver coincident with an increase
in histone acetylation (Figure 6E). Interestingly, lipin 1 shRNA
abolished the fasting-induced increase in PGC-1a occupation
and histone acetylation of the Acadm promoter. Taken together,
these findings suggest that lipin increases the recruitment of
PGC-1a and other coactivators with HAT activity, such as p300
to target promoters, resulting in an augmentation of transcription.205
A R T I C L EFigure 6. Lipin 1 interacts directly with PGC-1a
A) Results of Co-IP-Western blotting analyses using
protein isolated from liver of fed or fasted WT mice.
Proteins were immunoprecipitated using lipin 1 anti-
body followed by Western blotting analyses using
lipin 1 or PGC-1a antibodies. Lysates from fasted
PGC-1a2/2mice (2/2) or WT lysates using nonspe-
cific IgG antibodies are shown as negative controls
and whole-cell lysates from lipin or PGC-1a overex-
pressing cells included as positive controls. (bottom)
Representative autoradiographs depict results of
GST pull-down assays performed with GST-lipin fu-
sion proteins and recombinant PGC-1a.
B) Schematic depicts full-length PGC-1a protein
(top) including the relative location of 3 LXXLL motifs
required for interaction with nuclear receptors. C-ter-
minal PGC-1a truncation mutants are also shown.
Autoradiographs depict results of GST pull-down as-
says performed with GST control or GST-lipinDN
with 35S-labeled PGC-1a (full-length [797], 338,
191, or 120 amino acids [see schematic at top]) or
full-length PGC-1a harboring mutations in L1/2/3
(mL1/2/3) is shown. All truncation mutants begin
with aa 1 and mutant designations indicate their
C-terminal ends.
C) A schematic depicting the heterologous UAS.T-
KLuc reporter is shown inset. UAS.TKLuc was co-
transfected into CV1 cells with expression vector
driving expression of a Gal4-PGC-1a fusion protein
containing amino acids 1–797 or 1–120 of PGC-1a
protein (or Gal4 DNA binding domain [DBD] control)
in the presence or absence of lipin 1. *p < 0.05 versus
pCDNA vector control.
D) Results of Co-IP-Western blotting analyses using
protein isolated from liver of mice infected with
adenovirus driving expression of lipin 1 and/or
GFP. Proteins were immunoprecipitated using p300
antibody followed by Western blotting analyses us-
ing lipin 1 antibody. Nonspecific IgG antibody was
utilized with lipin overexpressing lysates as negative
controls.
E) The image depicts the results of ChIP assays
using chromatin from hepatocytes of fed or fasted
mice infected with adenovirus driving expression
LacZ shRNA (Lac), or lipin 1 shRNA (594). Chromatin
bound proteins were immunoprecipitated using antibody directed against lipin 1 or IgG control. ‘‘Input’’ represents 0.2% of the total chromatin used in the IP reactions.
Graphs depict the results of SYBR GREEN PCR analyses to quantify the results of ChIP experiments using antibodies directed against PGC-1a or acetylated histone H3
and chromatin from fed or fastedmouse liver infected with adenovirus driving expression LacZ shRNA (LacZ) or lipin 1 shRNA (594). PCR primers were designed to amplify
a region of the Acadm gene promoter known to respond to PGC-1a.Lipin-mediated activation of hepatic fatty acid oxidation
requires PGC-1a
To determine the requirement of PPARa or PGC-1a for lipin-me-
diated increases in target genes and hepatic fatty acid oxida-
tion, WT, PPARa2/2, or PGC-1a2/2mice were injected with ad-
enovirus overexpressing lipin-1b or GFP. The effects of lipin
were only partly altered in PPARa null mice. Specifically, the
lipin-mediated induction of a subset of target genes (Fabp1
and Acadvl) was blunted in the PPARa2/2 mice whereas other
targets (Cpt1a and Acadm) did not require the presence of
PPARa (Figure S2). It is likely that other transcription factors
such as PPARb/d and/or HNF4a, both of which are known to
regulateAcadm and other PPAR targets, support lipin-mediated
activation in the absence of PPARa.
In contrast to the results obtained with PPARa2/2mice, when
PGC-1a2/2 mice were employed, Northern blotting analyses
revealed that activation of Ppara, Cpt1a, Acadvl, and Acadm
expression in response to lipin 1 was completely abolished in
PGC-1a2/2mice (Figure 7A). Moreover, plasma b-hydroxybuty-206rate levels were not increased following lipin 1 overexpression in
PGC-1a2/2mice aswas observed inWT controls (Figure 7B). In-
terestingly, plasma TAG levels and Apoa4 expression were not
suppressed by lipin activation in PGC-1a2/2 mice (Figure 7C),
which seems at odds with the known stimulatory effects of
PGC-1a onApoa4 expression. Liver TAG content was increased
by lipin 1 in PGC-1a2/2mice (Figure 7C), potentially due in part to
the PAP activity of lipin or the reduced mitochondrial oxidative
capacity of PGC-1a-deficient mice (Burgess et al., 2006; Leone
et al., 2005). These findings indicate that PGC-1a is required for
the lipin 1-mediated activation of hepatic fatty acid oxidation.
Discussion
Mounting evidence implicates lipin 1 in the regulation of lipid and
energymetabolism. Herein, we demonstrate that the expression
of lipin 1 is rapidly induced in liver by fasting, glucocorticoids,
and insulin-deficiency in a PGC-1a-dependent manner. Gain-
of-function and loss-of-function strategies revealed that lipinCELL METABOLISM : SEPTEMBER 2006
Lipin regulates hepatic lipid metabolismFigure 7. Lipin 1 requires PGC-1a for target gene
activation in liver
A) Representative autoradiographs from Northern
blotting analyses using hepatic RNA from WT and
PGC-1a2/2 mice injected intravenously with adeno-
virus driving expression of lipin 1 (LPN) and/or green
fluorescent protein (GFP). Blots were sequentially
hybridized with the cDNA probes listed at left.
B) Graph depicts plasma b-hydroxybutyrate (HB)
levels in WT and PGC-1a2/2 mice infected with
GFP or lipin 1 adenovirus. *p < 0.05 versus GFP con-
trols.
C)Graph depicts plasma (left) or liver (right) triglycer-
ide levels in WT and PGC-1a2/2 mice infected with
GFP or lipin 1 adenovirus. *p < 0.05 versus GFP con-
trols.
D) A schematic representation of the involvement of
lipin 1 in the hepatic response to fasting. Physiologic
stimuli that dictate an increased cellular capacity
mitochondrial fatty acid oxidation, like fasting and
diabetes, induce PGC-1a gene expression which,
in turn, activates expression of lipin 1. Thus, lipin 1
increases PPARa activity by two mechanisms: tran-
scriptional activation of the PPARa gene and direct
coactivation of PPARa in cooperation with PGC-1a
and p300. Lipin is an inducible ‘‘booster’’ that serves
to amplify select pathways downstream of PPARa/
PGC-1a to meet the demands of increase delivery
of fatty acids to the liver.serves as an inducible coactivator of the PGC-1a-PPARa circuit
to increase hepatic capacity for mitochondrial fatty acid oxida-
tion. In addition, lipin 1 suppresses hepatic lipogenesis and tri-
glyceride secretion, while increasing triglyceride stores. These
results implicate lipin as an amplifier of the PGC-1a-PPARa reg-
ulatory limb in liver (Figure 7D) to maintain hepatic lipid balance
in the context of physiologic and pathophysiologic conditions
(fasting and diabetes) that increase lipid delivery to the liver.
PGC-1a serves as a transcriptional coactivator for multiple
metabolic pathways in liver including fatty acid oxidation, gluco-
neogenesis, and mitochondrial respiration (Lin et al., 2005a;
Spiegelman and Heinrich, 2004). The PGC-1a-PPARa circuit
functions to increase hepatic capacity for mitochondrial fatty
acid oxidation and ketogenesis in response to short-term star-
vation, when fatty acids serve as the chief energy substrate (Ker-
sten et al., 1999; Leone et al., 2005, 1999). We present evidence
that places lipin 1 within the PGC-1 regulatory pathway. Our re-CELL METABOLISM : SEPTEMBER 2006sults indicate that fasting triggers the induction of lipin 1 expres-
sion resulting in the activation of select limbs of the PGC-1a
cascade to increase expression of genes involved in fatty acid
b-oxidation, the TCA cycle, and the mitochondrial respiratory
chain (Figure 7D). Lipin activates the PPARa/PGC-1a regulatory
pathway via multiple mechanisms including cooperation with
PPARa and PGC-1a as well as transcriptional activation of the
PPARa gene. Our results also demonstrate that lipin 1 is capable
of interacting with other hepatic transcription factors including
HNF-4a, PPARb, and PPARg. However, lipin 1 appears to con-
fer selectivity within the PGC-1a cascade given that it does not
significantly coactivate or interact with ERRa, which is highly de-
pendent on PGC-1a for its activity (Huss et al., 2002). In addition,
lipin overexpression leads to diminished lipogenesis and TAG
secretion – both pathways recently defined as targets of the
PGC-1s (Lin et al., 2005b; Rhee et al., 2006;Wolfrum and Stoffel,
2006). This last result is puzzling given the mounting evidence207
A R T I C L Ethat PGC-1a stimulates lipoprotein secretion. The mechanisms
whereby lipin can inhibit hepatic TAG secretion are an area of
active investigation and will hopefully be unveiled by additional
studies.
Our finding that lipin 1 serves nuclear functions is consistent
with reports that the yeast homolog, SMP2, regulates transcrip-
tion (Santos-Rosa et al., 2005). Interestingly, SMP2 (also known
as Pah1) was also recently identified as a phosphatidic acid
phosphohydrolase (PAP) enzyme that catalyzes the penultimate
step in the triglyceride synthesis pathway (Han et al., 2006).
Mammalian lipin 1 proteins also possess PAP activity, suggest-
ing that this function is preserved in higher organisms (Han et al.,
2006) and (Figure 5E). We suggest that lipin is a multi-functional
protein that regulates lipid metabolism at several levels. It is
tempting to speculate that in response to increased hepatic
free fatty acid delivery during fasting, the PAP activity of lipin
serves to rapidly increase esterification of fatty acids into TAG
whereas the gene regulatory effects are aimed at bolstering the
capacity for b-oxidation and suppressing fatty acid synthesis.
The transcriptional regulatory effects of lipin 1 on hepatic lipid
metabolism are consistent with the hepatic phenotype of fld
mice. Fldmice are hyperlipidemic (Langner et al., 1989) and iso-
lated hepatocytes from neonatal fld mice exhibit reduced FAO
rates (Rehnmark et al., 1998). Our results indicate that hepatic
lipin 1activation lowerscirculating lipid levelsby reducing triglyc-
eride secretion and stimulating hepatic b-oxidation. We also
found that lipin 1 activates Fabp1 and represses Apoa4 expres-
sion, which are down-regulated (Fabp1) and activated (Apoa4),
respectively infldmouse liver (Langner et al., 1989). Interestingly,
consistent with the finding that lipin 1 increases PPARa expres-
sion, studies of pre-adipocytes from fld mice demonstrate that
lipin 1 is required for the induction of PPARg expression which
drives adipocyte differentiation (Peterfy et al., 2005; Phan
et al., 2004). Given that we detected a protein-protein interaction
between lipin 1 and PPARg, it is possible that lipin 1 also serves
as a coactivator of PPARg during adipogenesis.
Our observation that lipin 1 coactivates PPARa/PGC-1a in
liver appears to contradict recent work demonstrating dimin-
ished expression of PPAR target genes in skeletal muscle of
lipin-overexpressing transgenic mice and activation of fatty
acid oxidation pathways in skeletal muscle of fld mice (Phan
and Reue, 2005). However, transgenic lipin 1 overexpression
was shown to exert distinct tissue-specific effects on PPAR tar-
get gene expression in muscle versus adipose tissue (Peterfy
et al., 2005; Phan and Reue, 2005). It is possible, therefore,
that the regulatory effects of lipin 1 on PPAR or other nuclear re-
ceptors is influenced by cell-specific factors or signaling path-
ways. Lipin 1 has been shown to be phosphorylated in response
to insulin (Huffman et al., 2002), a hormone with profound regu-
latory effects upon intermediary metabolism and gene expres-
sion. Cellular signaling events including, but not limited to, insu-
lin signaling could alter cellular localization or interactions with
coactivator or corepressor proteins in a cell-specific manner.
The fasting inducibility of lipin and its role as an activator of
FAO andmitochondrial function strongly suggest that this factor
serves to match oxidative capacity with fatty acid delivery to
maintain hepatic lipid balance. Consistent with this notion, lipin
1 suppresses hepatic lipogenesis and TAG secretion, while in-
creasing TAG storage. Increased delivery of fatty acids and ex-
cessive hepatic lipogenesis are known to contribute to thedevel-
opment of obesity-related NAFLD (Browning and Horton, 2004).208It is believed that in this disease state, the endogenous andexog-
enous supply of fatty acids exceeds the capacity of the hepato-
cyte to oxidize this substrate. Similarly, chronic alcohol exposure
also leads to lipid accumulation, potentially by reducing the oxi-
dative capacity of the hepatocyte (You and Crabb, 2004). Given
the effects of lipin 1 on hepatic oxidative capacity and circulating
TAGand free fatty acid levels, this factor couldprove to bea ther-
apeutic target for obesity-related dyslipidemia, NAFLD, and al-
coholic liver disease. However, given that our observations
that lipin increases hepatic TAG accumulation, it is difficult at
this point to predict the relative benefits versus detrimental ef-
fects of chronic lipin 1 activation on hepatic lipid balance.
In conclusion, we have found that lipin 1 is a hepatic PGC-1a
target gene that is robustly induced in response to conditions
that dictate increased fatty acid uptake and oxidative flux such
as fasting, glucocorticoids, and diabetes. Lipin 1 is also
a PGC-1a-interacting protein that coactivates selective targets
of the PGC-1a coactivation circuitry, including the entire PPAR
family. These results provide a possible mechanism for the se-
lective activation of distinct pathways within the PGC-1a regula-
tory cascade in response to physiologic stimuli, in this case,
serving to increase hepatic oxidative capacity and reduce lipo-
genic flux. Accordingly, we postulate that lipin 1 serves as an in-
ducible link betweenPGC-1a and a subset of its target transcrip-
tion factors to augment the capacity for hepatic mitochondrial
fatty acid catabolism and oxidative phosphorylation.
Experimental procedures
Animal studies
PGC-1a2/2 (Leone et al., 2005) and PPARa2/2 mice (Lee et al., 1995) have
been described. Diabetic db/dbmice were purchased from Jackson Labora-
tories (Bar Harbor, ME) and were sacrificed at 10 weeks of age for tissue col-
lection. Breeding pairs of fld mice (fld/fld 3 fld/+) were obtained from Jack-
son Laboratories and 7-day-old fld/fld and fld/+ (heterozygote) littermate
control mice were sacrificed for tissue collection.
Short-term fasting studies were performed with individually-housed mice
which were either food deprived for 24 hr (beginning at 0900) or given ad li-
bitum access to standard rodent chow. Insulin-deficient diabetes was in-
duced by intraperitoneal injection of the pancreatic b cell toxin, streptozoto-
cin (180 mg/kg body weight). Diabetic and saline-injected control mice were
sacrificed 7 days after injection. A single bolus intraperitoneal injection of
dexamethasone 21-phosphate (500 mg/kg) was administered 5 hr prior to
sacrifice for tissue collection. Hepatic lipin 1 overexpression or shRNA-medi-
ated knockdown was achieved by intravenous administration of adenoviral
vectors as previously described (Bernal-Mizrachi et al., 2003). Mice were
sacrificed 5 days after adenovirus administration.
Mammalian cell culture and transient transfections
CV1 and HepG2 cells were maintained in DMEM-10% fetal calf serum. Tran-
sient transfections were performed by calcium-phosphate coprecipitation.
The wild-type and HNF4-RE mutant human PPARa promoter (gift of B.
Staels), (ACO)3-TK-Luc, Gal4-responsive (UAS)3-TK-Luc (gift of D. Moore),
and Gal4-PPARa and Gal4-PGC-1a fusion protein expression vector con-
structs have been described (Barger et al., 2000; Huss et al., 2004; Pineda
Torra et al., 2002; Vega et al., 2000). PGC-1a and PPARa were overex-
pressed using pCDNA3.1-Myc/His.PGC-1a and pEFBOS-PPARa expres-
sion constructs, respectively.
Northern and Western blotting analyses
Northern blotting analyses were performed as described (Kelly et al., 1989)
using radiolabeled cDNA probes. Western blotting studies were performed
with whole-cell lysates using rabbit-derived antibodies directed against lipin
1 (Huffman et al., 2002), Flag epitope, (SigmaChemical, St. Louis, MO), PGC-
1a (Santa Cruz Biotechnology), or actin (Sigma Chemical Co.).CELL METABOLISM : SEPTEMBER 2006
Lipin regulates hepatic lipid metabolismIn Co-IP experiments, cells were lysed and incubations performed in
NP40-containing lysis buffer (20 mM Tris HCl, 100 mM NaCl, 0.5% NP40,
0.5 mM EDTA, 0.5 mM PMSF, and protease inhibitor cocktail). Proteins
were IPed using protein A-conjugated agarose beads and antibodies di-
rected against lipin 1 (Huffman et al., 2002), p300 (Upstate Biotechnology),
or the epitope tags of HA-lipin 1 (Covance Research Products), Flag-PPARa
or Flag-PPARg (Sigma Chemical Co), or PGC-1a-myc (Santa Cruz Biotech-
nology). Precipitated proteins were electrophoresed on acrylamide gels
followed by Western blotting analyses.
Adenoviral constructs
The adenoviral constructs driving expression of myc-tagged PGC-1a and/or
green fluorescent protein (GFP) has been previously described (Lehman
et al., 2000). Similarly, full-length HA-tagged lipin 1b and GFP was overex-
pressed using the Ad-EASY system. Lipin 1 shRNA constructs were de-
signed to target nucleotides 594–613 (sh594) or 896–915 (sh896) of the lipin
1 transcript and were cloned into the Invitrogen pENTR vector and then
recombined with the BLOCK-iT adenoviral RNAi expression system (Invitro-
gen). Adenoviral-driven shRNA constructs targeted to LacZ were utilized as
vector controls.
GST pull-down
GST pull-down studies were performed as described (Huss et al., 2002). GST
fusion protein constructs containing amino acids 1-641 or 640-924 of lipin 1
protein were generated using EcoRI digest of expression vector constructs
containing the truncated cDNAs and subsequent ligation into pCMX vector
backbone. The GST-PPARa and GST-PGC-1a 338 (amino acids 1–338) ex-
pression constructs have been described (Vega et al., 2000). The 891 (lipin
1a) and 924 (lipin 1b) amino acid forms of lipin 1 and full-length lipin 3 cDNAs
were fused to N-terminal HA tags and overexpressed using pCDNA3.1. The
lipin IIXXI and LXXILmotifs (amino acid 709–713 and 722–726) of lipin 1b pro-
tein were changed to FFXXI and LXXFF by site directed mutagenesis (Quick-
change; Strategene Inc.) using the pcDNA3.1-HA.lipin 1b vector as a tem-
plate. The aspartate 712 residue was changed to glutamate (D712E) by the
same technique. Full-length recombinant 35S-labeled protein was synthe-
sized using the TNT quickcoupled in vitro transcription/translation system
(Promega) and the respective pcDNA3 expression vectors. To produce
PPARa protein lacking the AF2 domain or the ligand binding domain, stop
codons were introduced at codon 450 or 288 respectively. Truncated
PGC-1a proteins were generated by introducing stop codons at codon
338, 191, or 120. PGC-1a proteins containing mutations in the L1/L2/L3
motifs have been described (Huss et al., 2002).
Statistical analyses
Statistical comparisons were made using analysis of variance (ANOVA)
coupled to Scheffe’s test. All data are presented as the mean 6 SEM, with
a statistically significant difference defined as a p value < 0.05.
Supplemental data
Supplemental data include Supplemental Experimental Procedures, Supple-
mental References, two supplemental tables, and two supplemental figures
and can be found with this article online at http://www.cellmetabolism.org/
cgi/content/full/4/3/199/DC1/.
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